TAT-cyclo-CLLFVY
Purity: ≥95%
Biological Activity
TAT-cyclo-CLLFVY is a selective HIF-1 dimerization inhibitor. Blocks protein-protein interaction of recombinant HIF-1α, but not HIF-2α, with HIF-1β (IC50 = 1.3 μM). Inhibits hypoxia-induced HIF-1 activity, and decreases VEGF and CAIX expression in osteosarcoma and breast cancer cells in vitro. Also reduces tubularization of hypoxic HUVECs.Technical Data
(Modifications: Lactam bridge: Cys-1 to Tyr-6), Disulfide bridge: 1-1*)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Background References
-
A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells.
Miranda E, Nordgren IK, Male AL et al.
J Am Chem Soc.
Product Datasheets
Citation for TAT-cyclo-CLLFVY
The citations listed below are publications that use Tocris products. Selected citations for TAT-cyclo-CLLFVY include:
1 Citation: Showing 1 - 1
-
CAMK2/CaMKII activates MLKL in short-term starvation to facilitate autophagic flux.
Authors: Ying Et al.
Autophagy 2022;18:726-744
FAQs
No product specific FAQs exist for this product, however you may
View all Peptide FAQsReviews for TAT-cyclo-CLLFVY
There are currently no reviews for this product. Be the first to review TAT-cyclo-CLLFVY and earn rewards!
Have you used TAT-cyclo-CLLFVY?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image